Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Ovarian Neoplasms 1Neoplasms, Plasma Cell 1Neoplasms by Histologic Type 1Neoplasms 1Multiple Myeloma 1Lymphoma, Mantle-Cell 1Lymphoma 1Hematologic Neoplasms 1Hematologic Diseases 1Fallopian Tube Neoplasms 1Blood Protein Disorders 1

Interventions

Dexamethasone 32Cyclophosphamide 30fludarabine phosphate 25Melphalan 25Busulfan 25Bortezomib 21Tacrolimus 20Lenalidomide 19Peripheral Blood Stem Cell Transplantation 18Mycophenolic Acid 17Whole-Body Irradiation 16Antilymphocyte Serum 16fludarabine 14Calcium Dobesilate 13Thalidomide 12Filgrastim 12Granulocyte Colony-Stimulating Factor 11Methotrexate 10pomalidomide 9Cyclosporine 8Radiotherapy 6Etoposide 6Cord Blood Stem Cell Transplantation 6Surveys and Questionnaires 5Stem Cell Transplantation 5Rituximab 5Methylprednisolone 5sargramostim 4carfilzomib 4Sirolimus 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Neoplasms, Plasma Cell × ricolinostat × Clear all
NCT01997840 2025-03-04

ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Low-dose Dex in Relapsed-and-Refractory Multiple Myeloma

Celgene

Phase 1/2 Terminated
103 enrolled 21 charts
Plasma cell

Blood Protein Disorders, Hematologic Diseases, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡